|PHARMACEUTICAL INDUSTRY NEWS
European Panel Supports Macugen [9/16/2005]
A European regulatory committee is recommending approval of
Macugen, a treatment for an eye disease called wet age-related
macular degeneration, in European Union countries.
Eyetech and Pfizer co-promote Macugen in the U.S. Eyetech,
which is planning to merge with OSI Pharmaceuticals, granted
Pfizer the exclusive rights to commercialize Macugen in other
nations by way of a licensing agreement.
Eli Lilly and Indian Firm to Develop Drug [Sept 15, 2005]
BANGALORE, India - U.S. pharmaceutical giant Eli Lilly and Co.
plans to work with an Indian firm to develop a drug that uses
benign viruses to kill the deadly E. coli bacteria in cattle, the
Indian company said Thursday.
Impax says FDA approves generic diabetes drug[ Sep 14, 2005]
NEW YORK, (Reuters) - Drugmaker Impax Laboratories Inc. said
U.S. regulators approved its generic version of Bristol-Myers
Squibb's diabetes drug Glucophage XR.
Pfizer receives European Approval to market Aromasin?for a
new indication, adjuvant treatment of estrogen receptor
positive invasive early breast cancer following two-to-three
years of initial adjuvant tamoxifen therapy in postmenopausal
women. [Press Release] PR Newswire Sept 13
Pfizer-Vicuron deal cleared by U.S.[ Sep 11]
Drugmakers Pfizer Inc. and Vicuron Pharmaceuticals Inc. said on
Sept 12 that Pfizer's proposed $1.9 billion acquisition of Vicuron
has cleared a federal antitrust review, and will be completed on
Sept 14. CNN Money - Sep 11 4:42 PM
Voyager files for $128.9 mln IPO [Fri Sep 9]
WASHINGTON (Reuters) - Voyager Pharmaceutical Corp. filed on
Friday to raise up to $128.9 million in an initial public offering of
Andrx Plant Halted By FDA [RedNova - Sep 08]
The Food and Drug Administration is placing all new drug
applications of Andrx on hold because of problems inspectors
found in its main manufacturing plant, the Davie drug maker
announced Tuesday. The news sent Andrx's stock plummeting.
Caremark Pays $137.5M to Settle Case [Sep 8, 5:25 PM ET[
NASHVILLE, Tenn. - Pharmacy benefits manager Caremark and
the Justice Department agreed Thursday to a $137.5 million
settlement of lawsuits originally filed by whistleblowers claiming
a predecessor company received kickbacks affecting several
federal health care programs.
Wyeth Pharmaceuticals Opens Ireland Plant
Thu Sep 8,10:24 AM ET
DUBLIN, Ireland - Wyeth Co. officially opened a $2 billion Irish
production facility Thursday, a move that will make the U.S.
company the biggest pharmaceutical employer in Ireland.
Novartis to Acquire Alnylam Pharma Stake
Wed Sep 7, 6:12 PM ET
NEW YORK - Swiss drug maker Novartis AG said Wednesday it
will acquire nearly 20 percent of Cambridge, Mass.-based
biopharmaceutical company Alnylam Pharmaceuticals Inc., as
part of a deal to develop drugs based on manipulating natural
Barr, Teva to Sell Generic Allegra
Tue Sep 6, 6:12 PM ET
WOODCLIFF LAKE, N.J. - Barr Pharmaceuticals Inc. and Teva
Pharmaceutical Industries Ltd. Tuesday said they would
cooperate in launching generic versions of Sanofi-Aventis'
Allegra allergy drug.
Chiron Stock Up on Takeover Speculation
Tue Sep 6, 5:03 PM ET
SAN FRANCISCO - Chiron Corp.'s stock continued to climb
Tuesday as investors bet that the recently troubled
biotechnology company will remain a takeover target despite its
rejection of a $4.5 billion acquisition bid by Swiss
pharmaceutical giant Novartis AG.
Teva, Barr joining to launch generic Allegra
Tue Sep 6,12:11 PM ET
CHICAGO (Reuters) - Barr Pharmaceuticals Inc. and Teva
Pharmaceutical Industries on Tuesday said they have entered
into an agreement to launch a generic version of Sanofi-Aventis'
Allegra allergy tablet before a U.S. court rules on patent
challenges. The news lifted the shares of Teva and Barr, while
sending Sanofi shares down by as much as 1.5 percent.
AstraZeneca CEO says no need for talks
Mon Sep 5, 7:08 AM ET
STOCKHOLM (Reuters) - AstraZeneca Plc's outgoing chief
executive poured cold water on the idea that the drug maker
might merge with GlaxoSmithKline Plc , saying on Monday it had
no reason to enter merger talks.
Novartis Offers $4.5 Billion for Chiron
Thu Sep 1, 5:31 PM ET
SAN FRANCISCO - The Swiss pharmaceutical giant Novartis AG
said Thursday it is offering $4.5 billion in cash to take over the
pioneering Northern California biotechnology company Chiron
Corp., which has fallen on hard times recently.
Novartis bids 4.5 billion dollars for control of Chiron
Thu Sep 1,10:58 AM ET
BASEL, Switzerland (AFP) - Swiss pharmaceutical group
Novartis said it had made an offer to the board of US laboratory
Chiron of 4.5 billion dollars (3.66 billion euros) for the 57.8
percent of the business it does not already own.
Companies Move to Donate to Katrina Relief
Wed Aug 31, 7:12 PM ET
Pharmaceutical companies rounded up much-needed medicine,
water suppliers loaded trucks with thirst-quenching cargo and
companies from petroleum giants to beer makers pitched in
millions in cash and products Wednesday to help communities
battered by Hurricane Katrina.
Sanofi-Aventis posts profit gain; share price tumbles on pipeline
Wed Aug 31, 3:14 PM ET
PARIS (AFP) - Pharmaceutical group Sanofi-Aventis reported a
26 percent rise in second-quarter net profit from a year ago but
its share price fell sharply on a mixed picture for new product
ImClone seeks Erbitux approval
Tue Aug 30, 3:36 PM ET
CHICAGO (Reuters) - ImClone Systems Inc. said on Tuesday it
was seeking U.S. regulatory approval to use colon cancer drug
Erbitux in head and neck cancer after a previous filing delay.
U.S. OKs Takeda Combined Diabetes Drug
Tue Aug 30, 8:29 AM ET
TOKYO - Takeda Pharmaceutical Co. has obtained approval from
the U.S. Food and Drug Administration for its new drug for
diabetes treatment and will begin selling it in October, the
company said Tuesday.
Calif. Targets 39 Companies in Drug Suit
Fri Aug 26, 1:04 AM ET
LOS ANGELES - California regulators named 39 new defendants
Thursday in a lawsuit against U.S. pharmaceutical companies
accused of inflating drug prices and costing state taxpayers
hundreds of millions of dollars.
California sues 39 drug makers
Thu Aug 25, 7:20 PM ET
LOS ANGELES (Reuters) - California's attorney general said on
Thursday the state has filed a lawsuit accusing 37 more
pharmaceutical companies of bilking the state's Medicaid
program of hundreds of millions of dollars by inflating drug
EU approves J&J purchase of Guidant
Thu Aug 25, 6:19 AM ET
BRUSSELS (Reuters) - Healthcare company Johnson & Johnson
conditionally won European Commission approval on Thursday
to buy rival medical device maker Guidant Corp. for $25.4 billion
in cash and stock.
Roche, WHO strike deal on global stockpile of anti-flu drugs
Wed Aug 24, 2:23 PM ET
GENEVA (AFP) - The Swiss pharmaceutical giant Roche said it
would donate enough anti-flu drugs for three million people to
the UN health agency's new global stockpile for a threatened
OSI Pharmaceuticals Agrees to Buy Eyetech
Mon Aug 22, 4:59 PM ET
NEW YORK - OSI Pharmaceuticals Inc., which focuses on cancer
treatments, has agreed to purchase Eyetech Pharmaceuticals
Inc. for about $935 million in stock and cash.
GlaxoSmithKline downplays concerns about top antidepressant
Mon Aug 22,12:54 PM ET
LONDON (AFP) - British pharmaceuticals giant GlaxoSmithKline
played down concerns about its antidepressant drug Seroxat
after a reported study claimed users had experienced an
increased suicide rate.
OSI Pharma to buy Eyetech for $935 mln
Mon Aug 22, 9:32 AM ET
NEW YORK (Reuters) - OSI Pharmaceuticals said on Sunday it
agreed to buy eye disease treatment maker Eyetech
Pharmaceuticals Inc. for around $935 million in cash and stock.
Merck plans legal fight after jury awards widow 253 million
Sat Aug 20,11:39 PM ET
WHITEHOUSE STATION, New Jersey, (AFP) - US pharmaceutical
giant Merck and Co. said it will continue to fight to prove its
innocence after a Texas jury found it guilty in a wrongful death
case brought by the widow of a man who died after using its
blockbuster arthritis painkiller Vioxx.
GeoPharma injects itself in antibiotics
BizJournals - Aug 16 8:18 AM
GeoPharma Inc. has acquired substantially all of the assets of
Consolidated Pharmaceutical Groups Inc., an antibiotic
manufacturer.The acquired assets include five ANDAs, or
abbreviated new drug applications, with 10 dosage strengths
and intellectual property for manufacturing the products.
PUBLISHER IS NOT REPONSIBLE FOR THE ACCURACY. YOU SHOULD
DISCUSS WITH YOUR CONSULTANT FOR ANY
INVESTMENT OR PRODUCT DEVELOPMENT. ALL RIGHT RESERVED 2005